Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy
AbstractCardiovascular diseases (CVDs) are currently among the leading causes of death worldwide. Platelet aggregation is a key cellular component of arterial thrombi and major cause of CVDs. Protease-activated receptors (PARs), including PAR1, PAR2, PAR3 and PAR4, fall within a subfamily of seven-transmembrane G-protein-coupled receptors (GPCR). Human platelets express PAR1 and PAR4, which contribute to the signaling transduction processes. In association with CVDs, PAR4 not only contributes to platelet activation but also is a modulator of cellular responses that serve as hallmarks of inflammation. Although several antiplatelet drugs are available on the market, they have many side effects that limit their use. Emerging evidence shows that PAR4 targeting is a safer strategy for preventing thrombosis and consequently may improve the overall cardiac safety profile. Our present review summarizes the PAR4 structural characteristics, activation mechanism, role in the pathophysiology of diseases and understanding the association of PAR4 targeting for improved cardiac protection. Conclusively, this review highlights the importance of PAR4 antagonists and its potential utility in different CVDs. View Full-Text
Share & Cite This Article
Rwibasira Rudinga, G.; Khan, G.J.; Kong, Y. Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy. Int. J. Mol. Sci. 2018, 19, 573.
Rwibasira Rudinga G, Khan GJ, Kong Y. Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy. International Journal of Molecular Sciences. 2018; 19(2):573.Chicago/Turabian Style
Rwibasira Rudinga, Gamariel; Khan, Ghulam J.; Kong, Yi. 2018. "Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy." Int. J. Mol. Sci. 19, no. 2: 573.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.